---
title: "Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283190100.md"
description: "LifeSci Capital analyst Charles Zhu has maintained a Buy rating on Kura Oncology, setting a price target of $28.00. His recommendation is based on promising clinical data from the FIT-001 study, where the combination of darlifarnib and cabozantinib showed response rates exceeding expectations. Zhu notes the manageable safety profile and early signs of treatment durability, supporting a favorable risk-reward scenario in the post-IO renal cell carcinoma setting."
datetime: "2026-04-17T20:05:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283190100.md)
  - [en](https://longbridge.com/en/news/283190100.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283190100.md)
---

# Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating

LifeSci Capital analyst Charles Zhu maintained a Buy rating on Kura Oncology today and set a price target of $28.00.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Charles Zhu has given his Buy rating due to a combination of factors tied to Kura’s emerging clinical data and strategic positioning in renal cell carcinoma. He views the updated results from the FIT-001 study, where darlifarnib is combined with cabozantinib in post-cabo clear cell RCC, as particularly compelling because the response rates materially exceed what would be expected from cabozantinib retreatment alone.

Zhu also highlights that several responses occurred in patients who had previously derived only stable disease or who had recently progressed on cabozantinib, suggesting meaningful resensitization to VEGF TKI therapy. In his view, the manageable safety profile at full-dose cabozantinib, early signals of durability, and evidence of investigator enthusiasm in a high-unmet-need, post-IO setting together support a favorable risk‑reward and justify a continued Buy recommendation on KURA.

### Related Stocks

- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)